Abstract
Background
Multiple sclerosis (MS) occurs as a result of interaction between genetic and environmental
factors. Recent data support the view that oxidative damage is one of an early event
in MS tissue injury. The safe elimination of reactive oxygen species and toxins via
glutathione S-transferase (GST) pathways is required in order to protect cells against
reactive oxygen-induced damage. The aim of our study was to analyze the possible association
of GSTM1 and GSTT1 gene polymorphisms with the susceptibility and clinical parameters
of MS, in 455 consecutive patients and 366 controls.
Methods
A multiplex polymerase chain reaction (PCR) was used to detect the deletions in GSTM1
and GSTT1 genes.
Results
Patients with MS had significantly higher frequency of GSTT1 null genotype compared
to controls (37.36% vs. 21.86%, respectively, p < 0.0001, adjusted OR 2.13 (1.56–2.90)), as well as double deletions (15.38% vs. 10.38%,
respectively, p < 0.05). The carriers of GSTM1 deletion had significantly earlier onset of MS compared
to the wild-type carriers (28.31 ± 8.45 vs. 30.64 ± 9.30 years, respectively, p = 0.03).
Conclusion
This study suggests the potential pathogenic role of GSTT1 deletion on MS susceptibility.
There are no similar data published so far, yet this study should be replicated in
other populations.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of the Neurological SciencesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Semin multiple sclerosis: lessons from neuropathology.Neurology. 1998; 18: 337-349
- Multiple sclerosis: candidate mechanisms underlying CNS atrophy.Trends Neurosci. 2010; 33: 202-210
- Evidence of early cortical atrophy in MS: relevance to white matter changes and disability.Neurology. 2003; 60: 1157-1162
- Oxidative damage to DNA in plaques of MS brains.Mult Scler. 1998; 4: 413-418
- Oxidized phosphatidylcholine is a marker for neuroinflammation in multiple sclerosis brain.J Neurosci Res. 2007; 85: 977-984
- Radical changes in multiple sclerosis pathogenesis.Biochem Biophys Acta. 1812; 2011: 141-150
- Oxidative damage in multiple sclerosis lesions.Brain. 2011; 134: 1914-1924
- The molecular basis of neurodegeneration in multiple sclerosis.FEBS Lett. 2011; 585: 3715-3723
- Structure and function of glutathione S-transferases.Biochim Biophys Acta. 1994; 1205: 1-18
- The glutathione S-transferase supergene family: regulation of GST and the contributions of the isoenzymes to cancer chemoprotection and drug resistance.CRC Crit Rev Biochem Mol Biol. 1995; 30: 445-600
- Structure, function and evolution of glutathione transferases: implications for classification of non-mammalian members of an ancient enzyme superfamily.Biochem J. 2001; 360: 1-16
- Glutathione transferases.Annu Rev Pharmacol Toxicol. 2005; 45: 51-88
- Oxidative stress in multiple sclerosis patients in clinical remission: association with the expanded disability status scale.J Neurol Sci. 2012; 321: 49-53
- Molecular epidemiology of the human glutathione S-transferase genotypes GSTM1 and GSTT1 in cancer susceptibility.Cancer Epidemiol Biomarkers Prev. 1997; 6: 733-743
- Human glutathione S-transferase theta (GSTT1): cDNA cloning and the characterization of a genetic polymorphism.Biochem J. 1994; 300: 271-276
- Glutatione S-transferase polymorfisms in MS: their relationship to disability.Neurology. 2000; 5: 542-544
- Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.Ann Neurol. 2011; 69: 292-302
- Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on clinical trials of new agents in multiple sclerosis.Neurology. 1996; 46: 907-911
- Multiple sclerosis severity score: using disability and disease duration to rate disease severity.Neurology. 2005; 64: 1144-1151
- Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS).Neurology. 1983; 33: 1444-1452
- Increased risk for myelodysplastic syndromes in individuals with glutathione transferase theta 1 (GSTT1) gene defect.Lancet. 1996; 347: 295-297
- Association between glutathione S-transferase M1, P1, and T1 genetic polymorphisms and development of breast cancer.J Natl Cancer Inst. 1998; 90: 512-518
- Power and sample size calculations: a review and computer program.Control Clin Trials. 1990; 11: 116-128
- Ethnic differences in the prevalence of the homozygous deleted genotype of glutathione S transferase theta.Carcinogenesis. 1995; 16: 1243-1245
- Metabolic gene polymorphism frequencies in control populations.Cancer Epidemiol Biomarkers Prev. 2001; 10: 1239-1248
- Glutathione-S-transferase T1 and M1 gene polymorphisms in Greek patients with multiple sclerosis: a pilot study.Eur J Neurol. 2007; 14: 572-574
- The patients with clinically isolated syndrome and relapsing remitting multiple sclerosis show different levels of advanced protein oxidation products and total thiol content in sera and csf.Neurochem Int. 2013; ([pii: S0197-0186(13)00070-3, Epub ahead of print])https://doi.org/10.1016/j.neuint.2013.02.025
- Free radical peroxidation products in cerebrospinal fluid and serum of patients with multiple sclerosis after glucocorticoid therapy.Folia Neuropathol. 2010; 48: 116-122
- Disruption of thiol homeostasis and nitrosative stress in the cerebrospinal fluid of patients with active multiple sclerosis: evidence for a protective role of acetylcarnitine.Neurochem Res. 2003; 28: 1321-1328
- Regulation by interferon beta-1a of reactive oxygen metabolites production by lymphocytes and monocytes and serum sulfhydryls in relapsing multiple sclerosis patients.Neurochem Int. 2003; 42: 67-71
- INF-β1b therapy modulates l-arginine and nitric oxide metabolism in patients with relapse remittens multiple sclerosis.J Neurol Sci. 2013; 323: 187-192
- Oxidative stress increases blood–brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation.J Cereb Blood Flow Metab. 2010; 30: 1625-1636
- GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset.Biochem Biophys Res Commun. 2000; 269: 676-680
- Association of GST M1 null polymorphism with Parkinson's disease in a Chilean population with a strong Amerindian genetic component.Neurosci Lett. 2007; 418: 181-185
- Geoparkinson study group. Gene–environment interactions in parkinsonism and Parkinson's disease: the Geoparkinson study.Occup Environ Med. 2007; 64: 673-680
- Vitamin C levels in blood are influenced by polymorphisms in glutathione S-transferases.Eur J Nutr. 2010; 50: 437-446
- Serum vitamin C and other biomarkers differ by genotype of phase 2 enzyme genes GSTM1 and GSTT1.Am J Clin Nutr. 2011; 94: 929-937
- Are glutathione S transferases involved in DNA damage signalling? Interactions with DNA damage and repair revealed from molecular epidemiology studies.Mutat Res. 2012; 736: 130-137
- Disease-specific molecular events in cortical multiple sclerosis lesions.Brain. 2013; 136: 1799-1815
- Glutathione transferases as mediators of signaling pathways involved in cell proliferation and cell death.Cell Death Differ. 2010; 17: 1373-1380
Article info
Publication history
Published online: August 12, 2013
Accepted:
July 8,
2013
Received in revised form:
July 5,
2013
Received:
April 10,
2013
Identification
Copyright
© 2013 Elsevier B.V. Published by Elsevier Inc. All rights reserved.
